Can C4AQUO Decreased Frequency Be Considered a Genetic Marker for Vitiligo and Familial Melanoma?

G. Orecchia, PhD, L. Perfetti, MD, M. Cuccia, PhD, O. Finco, PhD

Pavia, Italy

Letters to the Editor

Can C4AQUO Decreased Frequency Be Considered a Genetic Marker for Vitiligo and Familial Melanoma?

G. Orecchia, MD, L. Perfetti, MD, M. Cuccia, PhD, O. Finco, PhD, Dipartimento di Genetica e Microbiologia, dell'Università di Pavia, Via S. Epifanio 14, 27100 Pavia (Italy), Clinica Dermatologica, dell'Università di Pavia, P. le Golgi 2, 27100–Pavia (Italy)

Sir,

A decreased frequency of C4AQUO has been found in both vitiligo and familial melanoma patients. This allele might be regarded as a genetic marker possibly acting as a resistance factor for both diseases. The serum complement proteins are an important part of the mammalian immune response being required for the lysis of antibody-targeted cells [1,2]. Some of these proteins (C2, Bf, C4), characterized by a high polymorphism, are encoded by genes representing the class III of the major histocompatibility complex (MHC).

Class III was reported to be involved in melanoma, with decreased Bf-FF and increased Bf-S alleles [3,4], and in familial melanoma, with a decreased C4AQUO frequency [5]. Class III was referred to be involved also in sporadic vitiligo, with a decreased C4AQUO frequency [6]. These observations suggest a possible genetic connection between melanoma and vitiligo, and give support to the hypothesis, already proposed by some authors [7], who stated that ‘there is a genetically determined tendency of some pigment cells to be destroyed and yield some form of vitiligo or to become transformed to melanoma cells’. These authors hypothesized an immunological process ‘by which the presence of vitiligo can counteract the proliferation of melanoma cells’. Our two works [5, 6] should give credit to this hypothesis even if many points must be clarified: the possibility to find a common clue in such different phenomena (the uncontrolled proliferation of malignant melanocytes and the destruction of melanocytes) remains a matter for speculation.

Among the possible explanations we consider: (1) The protein encoded by C4AQUO is less efficient than those encoded by other alleles: as a result, a decreased frequency of this allele leads to an above average efficiency of the immune system which would be able to contrast, even if partially, malignant cells and would be responsible for an erroneous destruction of the delicate normal melanocytes. This hypothesis is confirmed by a greater survival rate of the patients with

78

Letters to the Editor
familial melanoma [8, 9]. (2) The protein encoded by C4AQO is more efficient than those
marked by other alleles: a decreased frequency of this allele (C4AQO) means an impaired
immune surveillance and a consequent incapacity to control toxic factors responsible for the
disappearance of melanocytes in vitiligo and for persistent stimulation resulting in malignant
deviation. In this way multiple familial melanomas and their earlier occurrence [8, 9] in life are
better explained. However it remains obscure what these noxious factors are: we cannot exclude
a virus acting directly [10, 11] on melanocytes insufficiently protected by an inefficient immune
system with an altered complement, or indirectly, by further damaging the immune system [12].
It must be stated that a reduced or increased activity of the complement system should interact
with different targets and not just with melanocytes. Indeed vitiligo is known to be associated
with different autoimmune diseases: such an association is not evident in familial melanoma but
it should be searched for carefully to gain further support for our hypothesis. In fact a more
active interaction between a particular complement phenotype and a specific antigenic target
(normal or genetically abnormal melanocyte and also other tissues) could be expected since
glycoproteins on the cell surface may offer a more or less accessible site for activation of C3 and
C4 [1].

In conclusion, a genetical predisposition for familial melanoma [3, 4, 8] and for vitiligo [6, 13,
14] has been already demonstrated: our observation of reduced frequency of C4AQO in both
diseases suggests the possibility of a common genetic marker, playing a role in the path-ogenesis
and/or in the evolution of these diseases and, in particular, acting as a resistance factor for
familial melanoma and for vitiligo.

Acknowledgements
We are grateful to Dr. A.B. Lerner, MD, for his invitation to visit his department in Yale: it was
a useful stimulus for our work. We are also grateful to Dr. M.T. Illeni of 1st. Nazionale per lo
Studio e la Cura dei Tumori for kindly referring the patients with familial melanoma to us.
Research partially supported by Fondazione ‘Pro Ricerca Dermatologica’.

References
Porter RR: Complement polymorphism, the major histocompati-bility complex and associated
Porter RR: The molecular genetics of the components of complement and autoimmune diseases.

Milton GW, Balch CM, Shaw HM: Clinical characteristics; in Balch CM, Milton GW (eds):
De Paoli F, Cuccia Belvedere M, Finco O, Illeni MT, Pellegris G, Cacinelli N: C4 and Bf
Lerner AB, Kirkwood JM: Vitiligo and melanoma: Can genetically abnormal melanocytes result
Bork K, Brauninger W, Nake A: Increased frequency of multiple familial melanomas in
Hereditary Angioedema and Oral Contraception

To the Editor

Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by a quantitative or functional deficiency of Cl esterase inhibitor (Cl-INH) [1]. Attacks of angioedema may be induced by a variety of factors, such as tissue trauma, infection, anxiety, and fatigue [1]. The condition apparently is further influenced by sexual hormones [2-4].

Case Report. A 20-year-old previously healthy woman was given Diane® (containing 0.035 mg ethinyl estradiol and 2 mg cyproterone acetate) as treatment for acne. Three weeks after institution of the therapy she experienced attacks of poorly circumscribed, nonpitting and nonpruritic cutaneous swellings, along with occasional abdominal pain. The edema involved particularly the extremities, the trunk and further pressure-exposed sites. The episodes lasted for up to 3 days and occurred weekly. After 2 months she changed to Trinordiol® (containing 0.05-0.125 mg levonorgestrel and 0.03-0.04 mg ethinyl estradiol) as oral contraceptive agent (OCA), but attacks persisted. She was therefore given Lutényl® (containing 5 mg of normegestrol acetate) and she was free of symptoms until she discontinued OCA 2 months later.

Responses to repeated pressure challenges were all the time negative. Extensive laboratory investigations, including search for autoantibodies, did not reveal any abnormalities, except of the complement profile (table 1).